Program Description
APOL1-mediated kidney disease (AMKD) is a progressive and highly heterogeneous form of chronic kidney disease (CKD) that may develop in individuals who have inherited 2 high-risk APOL1 gene variants. Although most carriers do not develop kidney disease at all, inflammation or infection signals can trigger APOL1 activity that damages podocytes and contributes to kidney failure. Management strategies have been adapted from supportive therapies associated with general CKD care, such as renin-angiotensin-aldosterone system and sodium-glucose cotransporter 2 inhibitors, but these do not directly target APOL1-mediated disease mechanisms. Genotype-targeted agents are advancing through clinical trials as disease-modifying options for AMKD, and pharmacists must be aware of their potential place in therapy to guide patients through an evolving treatment landscape.
Target audience: Specialty Pharmacists
Type of activity: Application
Release date: December 18, 2026
Expiration date: February 18, 2027
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Describe the disease burden and pathophysiology of APOL1-mediated kidney disease (AMKD), including the consequences of delayed recognition and the mechanisms of APOL1-mediated podocyte injury in patients with 2 high-risk variants
- Explore the limitations associated with the current standard of care and the mechanism of action and clinical evidence for emerging genotype-targeted AMKD therapies
- Illustrate the pharmacist’s role in AMKD management, including patient counseling on medication adherence and renal risk, genetic testing access, and collaborating with multidisciplinary care teams
Lana (Svetlana) Shalumova, PharmD, MBA, ACE, CSP
Manager of Clinical Services
Shields Health Solutions
Stoughton, MA
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through February 18, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Svetlana Shalumova, MBA, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Adam Welch, PharmD, MBA, FAPhA; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms